New therapies for heart failure: Is thalidomide the answer?

QJM: An International Journal of Medicine

Volumn 93, Issue 5, 2000, Pages 305-311

  Davey, P P ^a,b   Ashrafian, H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; BACTERIUM LIPOPOLYSACCHARIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CATECHOLAMINE; CD14 ANTIGEN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN; ETANERCEPT; GLYCOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PENTOXIFYLLINE; PYRROLIDINE DITHIOCARBAMATE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; URIC ACID; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; MOUSE; NEUROENDOCRINOLOGY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034102991     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/93.5.305     Document Type: Article

References (60)

1. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993; 14:1158-62.
2. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence [see comments]. Arch Intern Med 1990; 150:769-73.
3. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997; 18:208-25.
4. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341:577-85.
5. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy [letter]. Lancet 1990; 335:294-5.
6. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-41.
7. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure [see comments]. Circulation 1995; 92:1479-86.
8. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201-6.
9. Nozaki N, Yamaguchi S, Shirakabe M, Nakamura H, Tomoike H. Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. Jpn Circ J 1997; 61:657-64.
10. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93:704-11.
11. Ferrari R. Tumour necrosis factor in CHF: a double facet cytokine. Cardiovasc Res 1998; 37:554-9.
12. Fearns C, Loskutoff DJ. Role of tumor necrosis factor alpha in induction of murine CD14 gene expression by lipopolysaccharide. Infect Immun 1997; 65:4822-31.
13. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study [see comments]. Lancet 1999; 353: 1838-42.
14. Kapadia S, Oral H, Lee J, Taffet GE, Mann D. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997; 81:187-95.
15. Bozkurt B, Kribbs SB, Clubb FJ., Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97:1382-91.
16. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 1991; 266:24613-20.
17. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha [see comments]. Circulation 1998; 97:1375-81.
18. Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldman AM. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail 1997; 3:117-24.
19. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group [see comments]. Nat Genet 1999; 22:178-81.
20. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol 1998; 6:193-7.
21. Kubota T, McNamara DM, Wang JJ, et al. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 1998; 97:2499-501.
22. Ceconi C, Curello S, Bachetti T, Corti A, Ferrari R. Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium? Prog Cardiovasc Dis 1998; 48:25-30.
23. Ferrari R. The role of TNF in cardiovascular disease. Pharm Res 1999; 40:97-105.
24. Binder C, Schultz M, Hiddeman W, Oellerich M. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab Invest 1999; 79:1703-12.
25. Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 1999; 14:206-10.
26. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased Expression of Tumor Necrosis Factor-in Failing Human Myocardium After Mechanical Circulatory Support: A Potential Mechanism for Cardiac Recovery Circulation Circulation 1999; 100:1189-93.
27. Bloksma N, Hofhuis F, Benaissa-Trouw B, Willers J. Endotoxin-induced release of tumour necrosis factor and interferon in vivo is inhibited by prior adrenoceptor blockade. Cancer Immunol Immunother 1982; 14:41-5.
28. Gullestad L, Aukrist P, Ueland T, et al. Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34:2061-71.
29. Peeters AC, Netea MG, Kullberg BJ, Thien T, van der Mewer JW. The effect of renin-angiotensin system inhibitors on proibaand anti-inflammatory cytokine production. Immunology 1998; 94:376-9.
30. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure [see comments]. Circulation 1999; 99:3224-6.
31. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998; 351:1091-3.
32. Gruppo Italiano per lo Studio della Sopravvivenza nell'lnfarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:447-55.
33. Matsumori A, Shioi T, Yamada T, Matsui S, Sesayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994; 89:955-8.
34. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993; 329:149-55.
35. Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health 1999; 89:98-101.
36. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168:408-14.
37. Singal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-71.
38. Deaner P. Thalidomide for distressing night sweats in advanced malignant disease [letter]. Palliat Med 1998; 12:208-9.
39. Sharp M, Getty J, Klausner JD. Thalidomide use is associated with weight gain in HIV-1-positive clients [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:392.
40. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U.S.A. 1994; 91:4082-5.
41. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
42. Marriot JB, Muller GW, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999; 20(12):538-40.
43. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177:1675-80.
44. Turk BE, Jiang H, Liu JO. Binding of thalidomide to alphal-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U.S.A. 1996; 93:7552-6.
45. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81:219-23.
46. Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9:1625-30.
47. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999; 58 (Suppl 1):107-13.
48. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatotogy 1996; 23:1616-21.
49. Raje N, Anderson K. Thalidomide - a revival story. N Engl J Med 1999; 341(21):1606-8.
50. Klauber N, Browne F, Anand-Apte B, D'Amato RJ. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation 1996; 94:2566-71.
51. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709.
52. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130:66-9.
53. Harland CC, Steventon GB, Marsden JR. Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 1995; 49:1-6.
54. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83:376-82.
55. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation [see comments]. Eur Heart J 1998; 19:1814-22.
56. Dibbs Z, Kurrelmeyer K, Kalra D, et al. Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians 1999; 111:423-8.
57. Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 1999; 33:1935-42.
58. Andreassen AK, Nordoy I, Simonsen S, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998; 81:604-8.
59. Pye M, Rae AP, Cobbe SM. Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 1990; 63:228-30.
60. Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A, Vooletich MT, Farmer JA, Torre-Amione G. Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Chest 1999; 115:1170-4.